EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging

Yuxin Li, Yang Zhao, Aocai Yang, Yan Wang, Jiaxiang Xin, Yufan Chen, Xuewen Xing, Fei Liu, Yao Zou, Wei Zhao, Lin Song, Tao Gong and 1 more

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-04 · 18 (2)

DOI: 10.1002/dad2.70348 ↗

At a glance

Journal article in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, published online on 2026-05-28. Written by Yuxin Li and 12 co-authors. Institution: Department of Radiology Shandong Provincial Hospital Shandong First Medical University Jinan China. 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Natural Science Foundation of Shandong Province, China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

INTRODUCTION Lecanemab provides clinical benefits in early Alzheimer's disease (AD), but its longitudinal effects on brain structure, particularly cerebrospinal fluid (CSF) compartments, remain unclear. This study examined treatment‐associated structural changes using longitudinal MRI. METHODS Thirty‐one patients with mild cognitive impairment (MCI) or early AD underwent baseline and follow‐up (1–7 months) 3D T1‐weighted MRI during lecanemab treatment. Gray matter (GM), ventricular, choroid plexus (CP), and perivascular space (PVS) volumes were quantified. Longitudinal changes were analyzed with paired tests and linear mixed‐effects models (LMMs). RESULTS Significant GM volume reductions were observed in AD‐vulnerable regions (hippocampus, entorhinal cortex, precuneus), with increased CSF volumes. PVS volume showed a modest, non‐significant decline. CP enlargement was associated with ventricular expansion. DISCUSSION Lecanemab treatment was associated with coordinated parenchymal and CSF‐related structural changes. CP and PVS dynamics may represent potential MRI‐based markers for monitoring early AD.

Subjects

Author keywords

Alzheimer's diseaseCSF dynamicslecanemablongitudinal imagingstructural MRI

Authors and institutions

  • Department of Radiology Shandong Provincial Hospital Shandong First Medical University Jinan China.
  • Department of Neurology Shandong Provincial Hospital Shandong First Medical University Jinan China.
  • MR Research Collaboration Team Siemens Healthineers Ltd. Shanghai China.

Funding

  • Natural Science Foundation of Shandong Province
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Cite

APA

Li, Y., Zhao, Y., Yang, A., Wang, Y., Xin, J., Chen, Y., Xing, X., Liu, F., Zou, Y., Zhao, W., Song, L., Gong, T., & Wang, G. (2026). Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(2). https://doi.org/10.1002/dad2.70348

Vancouver

Li Y, Zhao Y, Yang A, Wang Y, Xin J, Chen Y, et al. Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(2). doi:10.1002/dad2.70348

BibTeX
@article{Li2026,
  author = {Li, Yuxin and Zhao, Yang and Yang, Aocai and Wang, Yan and Xin, Jiaxiang and Chen, Yufan and Xing, Xuewen and Liu, Fei and Zou, Yao and Zhao, Wei and Song, Lin and Gong, Tao and Wang, Guangbin},
  title = {Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging},
  journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
  year = {2026},
  volume = {18},
  number = {2},
  doi = {10.1002/dad2.70348}
}
Start for free →